Ociperlimab (TIGIT) + tislelizumab (PD-1) posts ~55% ORR in 1L NSCLC cohorts; 66% ORR in 1L ES-SCLC

Ociperlimab is an anti-TIGIT antibody combined here with tislelizumab, an anti–PD-1 antibody engineered to reduce Fcγ receptor binding; in AdvanTIG-105 (Phase I/Ib, open-label; NCT04047862), patients received ociperlimab 900mg + tislelizumab 200mg Q3W ± 4 cycles of platinum-doublet chemotherapy, then maintenance. In untreated cohorts, ORR was 55.0% in sqNSCLC (40/41 evaluable), 54.8% in non-sqNSCLC (42/43), 40.0% in PD-L1+ NSCLC (45/45), and 65.9% in ES-SCLC (41/43), with mPFS 8.2, 11.3, 5.5, and 4.9 months respectively; in checkpoint inhibitor–experienced NSCLC, ORR was 7.7% with mPFS 2.9 months. Grade 3–4 TR-TEAEs occurred in 58.5% (sqNSCLC), 60.5% (non-sqNSCLC), 20.0% (PD-L1+), 23.1% (IO-experienced), and 53.5% (ES-SCLC)—benchmarks to keep in mind include pembrolizumab + carbo/(nab-)paclitaxel in 1L metastatic sqNSCLC (KEYNOTE-407) with ORR 57.9% and mPFS 6.4 months, pembrolizumab + pemetrexed/platinum in 1L metastatic non-sqNSCLC (KEYNOTE-189) with ORR ~48% and mPFS 8.8 months, and atezolizumab + carboplatin/etoposide in 1L ES-SCLC (IMpower133) with ORR 60% and mPFS 5.2 months.